Bluejay Diagnostics (BJDX) Equity Ratio (2020 - 2026)

Bluejay Diagnostics' Equity Ratio history runs 7 years deep, the most recent figure standing at 0.75 for Q1 2026.

• In Q1 2026, Equity Ratio rose 1.95% year-over-year to 0.75; the TTM figure through Mar 2026 stood at 0.75 (up 1.95% YoY), while the FY2025 annual figure was 0.84, down 2.48% from the prior year.
• Equity Ratio came in at 0.75 for Q1 2026 at Bluejay Diagnostics, down from 0.84 in the prior quarter.
• In the past five years, Equity Ratio ranged from a high of 0.92 in Q2 2022 to a low of 0.59 in Q4 2023.
• A 5-year average of 0.79 and a median of 0.83 in 2025 frame the typical range for Equity Ratio.
• Across the five-year window, Equity Ratio soared 394.72% in 2022 and sank 30.34% in 2023, its largest moves.
• Bluejay Diagnostics' Equity Ratio stood at 0.85 in 2022, then slumped by 30.34% to 0.59 in 2023, then jumped by 44.74% to 0.86 in 2024, then retreated by 2.48% to 0.84 in 2025, then declined by 11.02% to 0.75 in 2026.
• According to Business Quant data, Equity Ratio over the past three periods registered 0.75, 0.84, and 0.76 for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison